drugset / Trial / NCT02522481

Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141

NCT02522481 ↗

Phase 3 Completed 175 enrolled Bracco Diagnostics, Inc
NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study was to assess the safety and efficacy of Lumason-enhanced dobutamine stress echo (CE-DSE) in subjects having a suboptimal left ventricular endocardial border delineation (LV EBD) at rest and who were scheduled for coronary angiography.

Timeline

Start
2015-09-24
Primary completion
2017-11-07
Completion
2018-02-25

Outcome

Mixed primary results

registry NUMBER CE-DSE - UE-DSE: Sensitivity: 8.0 percentage of participants NCT02522481 ↗

registry analysis (superiority test); CE-DSE - UE-DSE; p = 0.0896; McNemar NCT02522481 ↗

registry NUMBER CE-DSE - UE-DSE: Specificity: 33.7 percentage of participants NCT02522481 ↗

registry analysis (superiority test); CE-DSE - UE-DSE; p <0.0001; McNemar NCT02522481 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Lumason Diagnostic / imaging agent 2 ml Intravenous